Back to top

Taysha Gene Therapies price target raised to $15 from $12 at Baird

Baird raised the firm’s price target on Taysha Gene Therapies (TSHA) to $15 from $12 and keeps an Outperform rating on the shares. The firm updated...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Taysha Gene Therapies, Inc. (TSHA)